Reassessing 7+3 in AML: New Trial Data Challenge Status Quo

In an interview with Targeted Oncology, Richard Stone, MD, Dana-Farber Cancer Institute and Harvard Medical School, discusses the focus of his presentation at the Baptist Health Miami Cancer Institute’s 7^th Annual Immunotherapies Summit for Hematologic Malignancies, examining whether the long-standing 7+3 chemotherapy regimen is still the standard of care for patients with acute myeloid leukemia (AML).

For decades, 7+3—consisting of cytarabine plus an anthracycline—has been the backbone of induction therapy for fit adults with AML. However, evolving treatment options are prompting clinicians to reconsider whether less intensive approaches might achieve similar outcomes with improved tolerability.

A major driver of this discussion is the growing success of the combination of azacitidine (Vidaza) and venetoclax (Venclexta) in older or unfit patients with AML. This regimen has demonstrated meaningful response rates and survival benefits in that population, raising the question of whether it could be effective in younger or more fit adults as well. Preliminary uncontrolled studies suggested potential benefit, but prospective randomized data had been lacking.

Stone highlights results from the phase 2 PARADIGM trial (NCT04801797), a randomized prospective study comparing azacitidine plus venetoclax with traditional 7+3 induction in previously untreated adults with AML who do not have favorable-risk disease. According to the initial findings, patients randomized to azacitidine plus venetoclax experienced superior event-free survival compared with those receiving 7+3. Overall survival outcomes appeared similar between the 2 treatment arms. Notably, the azacitidine/venetoclax regimen was associated with lower toxicity than the intensive chemotherapy approach.

Despite these encouraging results, Stone emphasizes that several important questions remain. Full trial data have not yet been released, and subgroup analyses are limited. Additionally, longer follow-up will be required to determine whether the observed benefits persist over time.

As the therapeutic landscape for AML continues to evolve, these findings contribute to an ongoing debate about whether less intensive regimens could eventually replace traditional induction therapy for selected patients.

Read the full interview here.